首页|Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis

Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Background and Aims: Previous meta-analyses have shown that aspirin use may reduce the risk of hepatocel-lular carcinoma (HCC). However, the optimal dose, frequen-cy, and duration of aspirin use or the safety and efficacy of aspirin in target populations for HCC prevention remain unclear. The study aim was to investigate the efficacy and safety of aspirin for prevention of HCC. Methods: Publica-tions were retrieved by a comprehensive literature research of several databases. Based on a random-effects model, hazard ratios (HRs) and the corresponding 95％ confidence intervals (CIs) were used to assess the pooled risk. The dose-response relationship between aspirin use and HCC risk was assessed with a restricted cubic spline model. Results: Twenty-two studies were included in the meta-analysis. Aspirin use was associated with a reduced risk of HCC (HR=0.64, 95％ CI: 0.56–0.75). The effect was robust across sex and age; however, women and the non-elderly had the greatest benefit from aspirin use. The preventive effect was well reproduced in those with comorbidities. Daily use and long-term use of aspirin appeared to offer greater benefits. Aspirin 100 mg/d was associated with maximum reduction of HCC risk. Aspirin use did slightly in-crease the risk of bleeding (HR=1.14, 95％ CI: 1.02–1.27). Conclusions: Our meta-analysis confirmed that use of as-pirin significantly reduced the incident risk of HCC. Regular and long-term aspirin use offers a greater advantage. As-pirin use was associated with an increased risk of bleeding. We recommend 100 mg/d aspirin as a feasible dose for further research on primary prevention of HCC in a broad at-risk population.

AspirinHepatocellular carcinomaPreventionMeta-analysisDose-response analysis

Lun-Jie Yan、Sheng-Yu Yao、Hai-Chao Li、Guang-Xiao Meng、Kai-Xuan Liu、Zi-Niu Ding、Jian-Guo Hong、Zhi-Qiang Chen、Zhao-Ru Dong、Tao Li

展开 >

Department of General Surgery,Qilu Hospital,Shandong University,Jinan,Shandong,China

Department of Hepatobiliary Surgery,The second Hospital of Shandong University,Jinan,Shandong,China

Taishan Scholars Program for Young Expert of Shandong Province国家自然科学基金国家自然科学基金funds for Independent Cultivation of Innovative Team from Universities in Jinan

tsqn2016106482073200818741782020GXRC023

2022

10.14218/JCTH.2021.00257

临床与转化肝病杂志(英文版)

临床与转化肝病杂志(英文版)

ISSN：
年,卷(期)：2022.10(5)
  • 50